Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report
SHANGHAI, April 16, 2025 /PRNewswire/ -- On April 15, 2025, Henlius (2696.HK) released the "2024 Environmental, Social, and Governance (ESG) Report" (hereinafter referred to as the "ESG Report" or "Report"). This marks the sixth consecutive year that the company has submitted an ESG-related report to global stakeholders, comprehensively showcasing Henlius' remarkable achievements and steadfast commitment across 5 key ESG...
Porton Advanced’s End-to-End CDMO Solutions Accelerates IND Approval of Tasly’s Innovative Dual-Targeting CAR-T Therapy
SUZHOU, China, April 16, 2025 /PRNewswire/ -- April 12, 2025, Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM). As the exclusive...
Transforming Lives with TAVI: A Milestone in Aortic Stenosis Treatment
MANILA, Philippines, April 16, 2025 /PRNewswire/ -- The Philippine Heart Center has reached a significant milestone by successfully performing six Transcatheter Aortic Valve Implantation (TAVI) procedures in a single day. This groundbreaking technique offers a minimally invasive alternative to open-heart surgery for patients with severe aortic stenosis, transforming lives and improving outcomes. The procedures were led by an expert...
Global Health Innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact
Winners of the ADGHW Innovation Awards 2025 addressed prenatal gene editing, robotic organ transplantation, precision drug delivery, and novel pain treatments Recipients include the Children's Hospital of Philadelphia, University of Pennsylvania, King Faisal Specialist Hospital & Research Centre, BioSapien Inc., and Nobel Laureate Ardem Patapoutian The diverse range of applicants underscore...
Fullerton Health Indonesia Launches First Executive Health Screening Centre Offering Exclusive, Private and Customised Screening in Jakarta
JAKARTA, Indonesia, April 16, 2025 /PRNewswire/ -- Fullerton Health Indonesia today officially launched its first Executive Health Screening Centre (EHS) in Jakarta, the fifth such centre in the Fullerton Health Group's executive health screening portfolio across Asia. The 700-square metre centre on the ground floor of Mandiri Inhealth Tower in Mega Kuningan offers...
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months
SHANGHAI, April 16, 2025 /PRNewswire/ -- The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results of ziresovir, a novel RSV-targeted antiviral drug developed by Shanghai Ark Biopharmaceutical Ltd. The article, titled "Efficacy and safety of ziresovir in hospitalised...
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study. IPAX-Linz is a single-arm Phase 2...
XellSmart’s Allogeneic iPSC-derived Cell Therapies for Parkinson’s Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials
SUZHOU, China, April 15, 2025 /PRNewswire/ -- In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted by XellSmart Biopharmaceutical (Suzhou) Co., Ltd. for its universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy for the treatment of Parkinson's disease (PD), the second most common neurodegenerative disease worldwide....
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
HIGHLIGHTS The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee (SRC) after the successful completion of the Dose Escalation Phase to commence...
Pilatus Biosciences to Present Research on PLT012 at AACR 2025
Novel Immunometabolism Approach Targets Immune-Cold Solid Tumors DOVER, Del. and EPALINGES, Switzerland, April 15, 2025 /PRNewswire/ -- Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on its lead candidate, PLT012, at the American Association for Cancer Research (AACR) 2025 Annual Meeting. The presentations will include an oral symposium by co-founder and Chair of the Scientific...
